Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System.

Next Previous
Trial Profile

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Glaucoma; Ocular hypertension
  • Focus Pharmacodynamics
  • Sponsors Allergan

Most Recent Events

  • 29 Apr 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
  • 05 Feb 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014 according to ClinicalTrials.gov record.
  • 15 Mar 2012 Actual patient number is 215 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top